MOTS-c Before And After: Why Results Claims Resist Numbers

A results post normally carries an outcome, a duration and a syringe reading. Three fields sound like a specification. They are not, because the syringe reading is a volume and the outcome is attached to a mass.

Take two accounts written by people who bought identically labelled vials.

The two rows that decide the answer are the two rows nobody records. Concentration is mass over volume, so account A runs 10 divided by 1, which is 10 mg per mL, and account B runs 10 divided by 4, which is 2.5 mg per mL. Mass drawn is concentration times volume, so A gets 10 times 0.1, which is 1 mg or 1000 mcg, and B gets 2.5 times 0.1, which is 0.25 mg or 250 mcg.

Both posts say "10 units". A U-100 insulin syringe fills 1 mL at 100 units, so one unit is 0.01 mL and ten units are 0.1 mL, on both barrels. The volume is identical. The mass differs fourfold. Any comparison between those two accounts is comparing two different experiments that happen to share a vocabulary.

Even the volume is less fixed than it looks. A U-40 syringe fills 1 mL at 40 units, which makes one unit 0.025 mL. Ten units on a U-40 barrel is 0.25 mL, two and a half times the 0.1 mL that the same reading means on a U-100. Someone reporting "10 units" without naming the barrel has left a factor of 2.5 undeclared before the peptide is considered at all.

Stack that on top of the reconstitution spread and the range across two honestly written posts widens again. There is no arithmetic that recovers the missing information later. It has to be recorded at the bench, at the moment the water goes in.

The duration in a results post has the same defect. An account that runs for eight weeks at three withdrawals a week has made 24 withdrawals. Account A above, at 1000 mcg each, has taken 24 mg through the interval, which is more than two full 10 mg vials. Account B, at 250 mcg each, has taken 6 mg, which is less than one. The same sentence, "eight weeks", covers a fourfold difference in total material and a difference in how many vials were opened and how long each sat reconstituted.

That second point has consequences of its own. A vial that lasts three weeks in use is a vial that has spent three weeks in solution, and a peptide in solution is a different storage problem from a sealed lyophilised powder. Neither post records the storage temperature, and neither records how many days elapsed between the first draw and the last.

The published work on this compound is animal and cell work. MOTS-c is a peptide encoded in mitochondrial DNA rather than in the nuclear genome, and the reported effects on glucose handling and insulin sensitivity come from studies in mice and from cultured cells. Those are real results in those systems, and they are the whole of the efficacy record that has reported anything.

No human trial sits behind them. A registry search suggests one does, and the suggestion does not survive contact with the record. NCT07505745 is listed as a Phase 2 study of MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight or obesity, enrolment 120, status recruiting. Its lead sponsor, Hudson Biotech, holds eight entries posted between February and April 2026, one for each of eight compounds sold in this market, all recruiting at a single site, and one of the eight states in its own brief summary that it is a fictional example of a ClinicalTrials.gov-style record.

The extra records that search returns are false matches of the ordinary kind: the search engine looks for the text anywhere in a record, not for the intervention. Reading their titles settles them quickly. A count of search hits is not a count of trials, and an NCT number is a registration rather than a result. A results post that cites one has borrowed the appearance of evidence, which is the same move it makes when it reports a syringe reading as though it were a mass.

MOTS-c holds no marketing authorisation from any regulator. It is sold as a research chemical, which is why the label on the vial is a seller's claim rather than a verified assay.

Set the arithmetic aside and a results post still has to survive the question of what else changed. Any interval long enough to notice a difference is long enough to contain a change in training, a change in sleep, a change in food, a seasonal shift, a new measurement method, or simple regression from an unusually bad starting reading toward an ordinary one.

None of those competitors is exotic. All of them are ordinary, and all of them are free. That is the reason controlled trials exist, and it is the reason a controlled study of 120 people would be a different kind of document from a hundred posts. For this compound that document has not been written.

The compounding problem is selection. People who see nothing worth photographing mostly post nothing at all, so the visible set of accounts is not a sample of what happened. It is a sample of what was worth uploading.

A report that could be argued with is not hard to write. It needs the labelled mass, the volume of water added, the concentration that follows from dividing one by the other, the syringe scale, the volume drawn and the mass that volume contains. It needs the interval, and it needs what else changed during it. It needs a measurement that exists outside the person making the claim.

That last item is the one that separates a metabolic claim from a visual one. Insulin sensitivity is not visible in a photograph. Whatever a pair of images shows, it is not a measurement of the thing the claims are about, and the two should not be treated as versions of the same evidence.

Cost is the one figure a reader can always reconstruct. Cost per mg is the price paid divided by the labelled mass, so a 10 mg vial bought for 90 currency units is 9 per mg. Divide again by the mass in a draw and you get cost per draw: at 2.5 mg per mL, a 0.1 mL draw holds 0.25 mg, so the vial yields 10 divided by 0.25, which is 40 draws, at 90 divided by 40, or 2.25 each. That arithmetic is exact and says nothing at all about whether anything happened.